Lost in translation: preclinical studies on 3,4‐methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
3,4‐Methylenedioxymethamphetamine (MDMA) induces both acute adverse effects and long‐term neurotoxic loss of brain 5‐HT neurones in laboratory animals. However, when choosing doses, most preclinical studies have paid little attention to the pharmacokinetics of the drug in humans or animals. The recreational use of MDMA and current clinical investigations of the drug for therapeutic purposes demand better translational pharmacology to allow accurate risk assessment of its ability to induce adverse events. Recent pharmacokinetic studies on MDMA in animals and humans are reviewed and indicate that the risks following MDMA ingestion should be re‐evaluated. Acute behavioural and body temperature changes result from rapid MDMA‐induced monoamine release, whereas long‐term neurotoxicity is primarily caused by metabolites of the drug. Therefore acute physiological changes in humans are fairly accurately mimicked in animals by appropriate dosing, although allometric dosing calculations have little value. Long‐term changes require MDMA to be metabolized in a similar manner in experimental animals and humans. However, the rate of metabolism of MDMA and its major metabolites is slower in humans than rats or monkeys, potentially allowing endogenous neuroprotective mechanisms to function in a species specific manner. Furthermore acute hyperthermia in humans probably limits the chance of recreational users ingesting sufficient MDMA to produce neurotoxicity, unlike in the rat. MDMA also inhibits the major enzyme responsible for its metabolism in humans thereby also assisting in preventing neurotoxicity. These observations question whether MDMA alone produces long‐term 5‐HT neurotoxicity in human brain, although when taken in combination with other recreational drugs it may induce neurotoxicity. LINKED ARTICLES: This article is commented on by Parrott, pp. 1518–1520 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476‐5381.2012.01941.x and to view the the rebuttal by the authors (Green et al., pp. 1521–1522 of this issue) visit http://dx.doi.org/10.1111/j.1476‐5381.2012.01940.x
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Self-citationMithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674 · cited 3×
“The recent encouraging results on the value of MDMA as an adjunct to psychotherapy for treating post-traumatic stress disorder (Mithoefer et al., 2011) suggests that further clinical studies with MDMA will follow.”
BackgroundResultVollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448 · cited 2×
“This concern spread to unease by some investigators (Gijsman et al., 1999; McCann and Ricaurte, 2001) that the studies of Vollenweider and colleagues (Vollenweider et al., 1998; Liechti and Vollenweider, 2000a,b) should not have been undertaken.”
BackgroundInfluentialSubjective Reports of the Effects of MDMA in a Clinical Setting
Greer, G., & Tolbert, R. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472364 · Cited by 413 · cited 3×
“(2001) in a firm rebuttal of this contention pointed out that the dose used was based on a careful review of the literature and was in the lowest range required to reliably produce psychoactive effects (Downing, 1986; Greer and Tolbert, 1986; Grob et al., 1996, 1998; Vollenweider et al., 1999).”
BackgroundMechan, A., Yuan, J., Hatzidimitriou, G., Irvine, R. J., McCann, U. D., & Ricaurte, G. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300808 · Cited by 67 · cited 3×
“More sophisticated is the approach of Ricaurte and colleagues (McCann and Ricaurte, 2001; Mechan et al., 2006) who used the allometric approach, which takes relative animal size into account (Mordenti and Chappell, 1989; Boxenbaum and D’Souza, 1990) and proposes the equation: D D W W human animal…”
BackgroundMethod
Cited by
Feduccia, A. A., & Mithoefer, M. C. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.003 · Cited by 217
Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine
Dunlap, L. E., Andrews, A. M., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00155 · Cited by 106
MDMA as a Probe and Treatment for Social Behaviors
Heifets, B. D., & Malenka, R. C. (2016) · Cell · doi:10.1016/j.cell.2016.06.045 · Cited by 42
Metadata
- Authors
- Green, A., King, M., Shortall, S., & Fone, K.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-06-21
- Volume
- 166
- Issue
- 5
- Pages
- 1523-1536
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1487335348
- Cited by
- 75
- References
- 5
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lost in translation: preclinical studies on 3,4‐methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01819.x
- The paper
- Green, A., King, M., Shortall, S., & Fone, K. (2012). Lost in translation: preclinical studies on 3,4‐methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01819.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.